论文信息 - Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR/J Mice

Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR/J Mice

An increasing amount of evidence supports pleiotropic metabolic roles of the cannibinoid-1 receptor (CB1R) in peripheral tissues such as adipose, liver, skeletal muscle and pancreas. To further understand the metabolic consequences of specific blockade of CB1R function in peripheral tissues, we performed a 10-week-study with an anti-sense oligonucleotide directed against the CB1R in diet-induced obese (DIO) AKR/J mice. DIO AKR/J mice were treated with CB1R ASO Isis-414930 (6.25, 12.5 and 25 mg/kg/week) or control ASO Isis-141923 (25 mg/kg/week) via intraperitoneal injection for 10 weeks. At the end of the treatment, CB1R mRNA from the 25 mg/kg/week CB1R ASO group in the epididymal fat and kidney was decreased by 81% and 63%, respectively. Body weight gain was decreased in a dose-dependent fashion, significantly different in the 25 mg/kg/week CB1R ASO group (46.1±1.0 g vs veh, 51.2±0.9 g, p<0.05). Body fat mass was reduced in parallel with attenuated body weight gain. CB1R ASO treatment led to decreased fed glucose level (at week 8, 25 mg/kg/week group, 145±4 mg/dL vs veh, 195±10 mg/dL, p<0.05). Moreover, CB1R ASO treatment dose-dependently improved glucose excursion during an oral glucose tolerance test, whereas control ASO exerted no effect. Liver steatosis was also decreased upon CB1R ASO treatment. At the end of the study, plasma insulin and leptin levels were significantly reduced by 25 mg/kg/week CB1R ASO treatment. SREBP1 mRNA expression was decreased in both epididymal fat and liver. G6PC and fatty acid translocase/CD36 mRNA levels were also reduced in the liver. In summary, CB1R ASO treatment in DIO AKR/J mice led to improved insulin sensitivity and glucose homeostasis. The beneficial effects of CB1R ASO treatment strongly support the notion that selective inhibition of the peripheral CB1R, without blockade of central CB1R, may serve as an effective approach for treating type II diabetes, obesity and the metabolic syndrome.

[1] M. Dalboni,et al. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. , 2012, Cytokine.

[2] D. Piomelli,et al. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. , 2011, The Journal of clinical endocrinology and metabolism.

[3] J. Perrard,et al. Effect of the Cannabinoid Receptor‐1 Antagonist Rimonabant on Inflammation in Mice With Diet‐Induced Obesity , 2011, Obesity.

[4] V. Marzo,et al. Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle , 2011, Reviews in Endocrine and Metabolic Disorders.

[5] A. de Gottardi,et al. Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[6] Miguel Martín,et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age , 2010, Diabetologia.

[7] Aamir Suhail,et al. Adiponectin-induced ERK and Akt Phosphorylation Protects against Pancreatic Beta Cell Apoptosis and Increases Insulin Gene Expression and Secretion* , 2010, The Journal of Biological Chemistry.

[8] S. Ambudkar,et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. , 2010, The Journal of clinical investigation.

[9] F. Bermúdez-Silva,et al. The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning? , 2010, Pharmacology Biochemistry and Behavior.

[10] Masahiko Watanabe,et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. , 2010, Cell metabolism.

[11] B. Vergès,et al. CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice , 2010, Diabetes.

[12] O. Shirihai,et al. The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets , 2009, Obesity.

[13] Andreas Zimmer,et al. Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis , 2009, PloS one.

[14] O. Marsenic. Glucose control by the kidney: an emerging target in diabetes. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15] Yen-Wen Wu,et al. The clinical implications of blood adiponectin in cardiometabolic disorders. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[16] M. Pruniaux,et al. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[17] B. Oldfield,et al. The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure , 2009, Obesity.

[18] F. Bermúdez-Silva,et al. The role of the pancreatic endocannabinoid system in glucose metabolism. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[19] A. Scheen. The endocannabinoid system: a promising target for the management of type 2 diabetes. , 2009, Current protein & peptide science.

[20] J. Després,et al. Pleiotropic effects of rimonabant: clinical implications. , 2009, Current pharmaceutical design.

[21] T. Noda,et al. Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways* , 2009, Journal of Biological Chemistry.

[22] B. He,et al. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. , 2008, Cardiovascular research.

[23] P. Formisano,et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase , 2008, Molecular Pharmacology.

[24] D. Osei-Hyiaman,et al. Endocannabinoids and the Control of Energy Homeostasis* , 2008, Journal of Biological Chemistry.

[25] P. Dubový,et al. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review , 2008, Pharmacology Biochemistry and Behavior.

[26] G. Marsicano,et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. , 2008, The Journal of clinical investigation.

[27] G. Marsicano,et al. Cannabinoid Type 1 Receptor Blockade Promotes Mitochondrial Biogenesis Through Endothelial Nitric Oxide Synthase Expression in White Adipocytes , 2008, Diabetes.

[28] A. Pocai,et al. Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms , 2008, Nature Medicine.

[29] Alexandros Makriyannis,et al. Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome , 2008, Physiology & Behavior.

[30] F. Mulè,et al. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. , 2008, European journal of pharmacology.

[31] S. Friedman,et al. Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors. , 2008, Cell metabolism.

[32] R. Capasso,et al. Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High‐fat Diet , 2008, Obesity.

[33] F. Bermúdez-Silva,et al. Presence of functional cannabinoid receptors in human endocrine pancreas , 2008, Diabetologia.

[34] M. Nakata,et al. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors , 2008, Regulatory Peptides.

[35] P. Bernante,et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. , 2007, The Journal of clinical endocrinology and metabolism.

[36] P. Soubrié,et al. Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats , 2007, Hepatology.

[37] J. Girault,et al. Role of Cannabinoid Type 1 Receptors in Locomotor Activity and Striatal Signaling in Response to Psychostimulants , 2007, The Journal of Neuroscience.

[38] F. Bermúdez-Silva,et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. , 2007, European journal of pharmacology.

[39] N. Chavez-Tapia,et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[40] C. Trautwein,et al. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis , 2007, Hepatology.

[41] L. Moezi,et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptors , 2006, British journal of pharmacology.

[42] X. Miao,et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. , 2006, Cancer genetics and cytogenetics.

[43] M. Fasshauer,et al. Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[44] M. Maj,et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[45] J. Després,et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[46] Arya M. Sharma,et al. Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[47] P. Soubrié,et al. The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48] M. Palkovits,et al. Cocaine- and Amphetamine-Related Transcript Is Involved in the Orexigenic Effect of Endogenous Anandamide , 2005, Neuroendocrinology.

[49] K. Mackie,et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[50] J. Després,et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. , 2005, The Journal of clinical endocrinology and metabolism.

[51] M. Stock,et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice , 2005, International Journal of Obesity.